mRNA Vaccines: Moderna Leading Development

Pharmaceutical Technology, 01.29.2024, published an analyst comment, “Moderna leads the development of mRNA vaccines in infectious diseases.” The market for global messenger RNA (mRNA) vaccines currently consists entirely of vaccines for Covid-19, however mRNA vaccines for other infectious diseases are in late-stage development with several pharmaceutical companies, with Moderna leading this development. 

Moderna is currently in Phase III pipeline candidate development for Covid-19, influenza, RSV, and cytomegalovirus, as well as exploring the potential use of mRNA vaccines in Zika, Monkeypox, and herpes viruses. Moderna is the only company in the late-stage pipeline that is targeting mRNA vaccines against bacterial pathogens that cause Lyme disease.


For More Information: 

Read the Pharmaceutical Technology Analyst Comment

Read More LDA Articles on mRNA Vaccines